BREAST CANCER DIAGNOSTICS MARKET SHIFTS AFTER NEW AI MOLECULE DETECTS TUMORS 3 YEARS EARLIER THAN MAMMOGRAMS
A biotech startup just disrupted oncology. Their new AI-powered blood test, currently in clinical trials, identifies breast cancer biomarkers with 98.7% accuracy, up to three years before traditional imaging can spot a mass. This eliminates the diagnostic delay that currently costs patients their best survival odds. For CEOs, this means one thing: the multi-billion-dollar mammography and biopsy supply chain is now obsolete. Investors are already pivoting capital toward early-detection liquid biopsies, reshaping the $20B breast cancer diagnostics market within one quarter. Your portfolio or medical device line? Either adapt or get left behind.